| 103604-5 |
carBAMazepine 10,11-Epoxide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Carbamazepine 10,11-Epoxide [Mass/volume] in Urine |
|
ADD |
DefinitionDescription |
|
|
ng/ml |
|
|
|
|
|
|
DRUG/TOX |
|
103604-5 |
|
|
|
|
Both |
|
|
|
0 |
Carbamazepine EP Ur-mCnc |
|
|
|
N |
|
Carbamazapine; Carbamazepine EP; Carbamazepine metabolite; Carbamezapine; Carbazepine; CRBM; DRUG/TOXICOLOGY; Drugs; Epitol; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Tegretol; Teril; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103605-2 |
Paroxetine metabolite I |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Paroxetine metabolite I [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103605-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Paroxetine M-I Ur Cfm-mCnc |
|
|
|
N |
|
(3S,4R)-4-(4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenoxymethyl)piperidine); BRL-36610; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Metab; Metabolites; Metb; Paroxetine M-I; Paxil; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103606-0 |
Paroxetine metabolite II |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Paroxetine M-II [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103606-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Paroxetine M-II Ur Cfm-mCnc |
|
|
|
N |
|
(3S,4R)-4-(4-fluorophenyl)-3-(3-hydroxy-4-methoxyphenoxymethyl)piperidine); 2; BRL-36583; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Metab; Metabolites; Metb; Paroxetine M-II; Paxil; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103607-8 |
Paroxetine metabolite III |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Paroxetine metabolite III [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103607-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Paroxetine M-III Ur Cfm-mCnc |
|
|
|
N |
|
(3S,4R)-4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine); 3; BRL-35961; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Metab; Metabolites; Metb; Paroxetine M-III; Paxil; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 103608-6 |
Sulbactam+Durlobactam |
Susc |
Isolate |
Pt |
OrdQn |
Gradient strip |
|
ACTIVE |
Sulbactam+Durlobactam [Susceptibility] by Gradient strip |
|
ADD |
DefinitionDescription |
|
|
�µg/mL |
|
|
N/A |
|
|
|
ABXBACT |
|
103608-6 |
|
Gradient strip |
|
|
Observation |
|
|
|
0 |
Sulbactam+Durlobactam Islt Grad strip |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Epsilometer; Estrip; E-strip; Grad strip; Islt; Isol; MIC; Minimum inhibitory concentration; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: ANSWER_LIST_TYPE: New Answer List created and added to existing LOINC code 103608-6 per the request of the CDC NHSN; METHOD_TYP: The CDC does use many LAB concepts without a method and asks their client to define the method on their own.; |
0 |
| 103609-4 |
Imatinib ^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Imatinib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
ADD |
DefinitionDescription |
|
|
ug/L |
|
|
C29H31N7O |
|
|
|
DRUG/TOX |
|
103609-4 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Imatinib free base; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; STI571 |
2.77 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 10361-4 |
DNA single strand Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
DNA single strand IgM Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
10361-4 |
|
|
|
|
Both |
|
|
|
0 |
ssDNA IgM Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Deoxyribonucleic acid; DNass; Immune globulin M; Immunoglobulin M; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SS; ssDNA; Stranded; Strnd |
2.68 |
1.0i |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 103610-2 |
Pazopanib^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Pazopanib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
C21H23N7O2S |
|
|
|
DRUG/TOX |
|
103610-2 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Pazopanib 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UNITS: Updated to a valid UCUM unit; EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; |
0 |
| 103611-0 |
Sunitinib^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Sunitinib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
C22H27FN4O2 |
|
|
|
DRUG/TOX |
|
103611-0 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Sunitinib 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UNITS: Updated to a valid UCUM unit; EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; |
0 |
| 103612-8 |
N-Desethyl Sunitinib^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
N-Desethyl Sunitinib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
C20H23FN4O2 |
|
|
|
DRUG/TOX |
|
103612-8 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
N-DesethylSu 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; N-DesethylSu; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; EXAMPLE_UNITS: Updated to a valid UCUM unit; |
0 |
| 103613-6 |
Sunitinib.total^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Sunitinib total [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
SUN + DESUN = TSUN |
|
|
|
DRUG/TOX |
|
103613-6 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Sunitinib ttl 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Sunitinib ttl; Tot; Totl |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; EXAMPLE_UNITS: Updated to a valid UCUM unit; |
0 |
| 103614-4 |
Gefitinib^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Gefitinib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
C22H24ClFN4O3 |
|
|
|
DRUG/TOX |
|
103614-4 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Gefitinib 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; EXAMPLE_UNITS: Updated to a valid UCUM unit; |
0 |
| 103615-1 |
Erlotinib^24H post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Erlotinib [Mass/volume] in Serum or Plasma by LC/MS/MS --24 hours post dose |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
C22H23N3O4 |
|
|
|
DRUG/TOX |
|
103615-1 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Erlotinib 24h p SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
After; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.77 |
|
|
|
|
|
|
|
ug/L |
|
|
Release 2.78: EXAMPLE_UNITS: Updated to a valid UCUM unit; EXAMPLE_UCUM_UNITS: Updated to a valid UCUM unit; |
0 |
| 103616-9 |
Creatinine |
SCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Creatinine [Moles/volume] in Serum or Plasma by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
103616-9 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Creat SerPl LC/MS/MS-sCnc |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.77 |
2.77 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 103617-7 |
Helicobacter pylori Ab.IgG |
PrThr |
Bld |
Pt |
Ord |
IA |
|
ACTIVE |
Helicobacter pylori IgG Ab [Presence] in Blood by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103617-7 |
|
IA |
|
|
Both |
|
|
|
0 |
H pylori IgG Bld Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Blood; C pylori; Campylobacter pylori; EIA; ELFA; ELISA; Enzyme immunoassay; H pyl; H pylori; IAA; Immune globulin G; Immunoglobulin G; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SUDS; WB; Whole blood |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103618-5 |
Hepatitis B virus RNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Hepatitis B virus RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
copies/mL |
|
|
N/A |
|
|
|
MICRO |
|
103618-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HBV RNA # SerPl NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; DNA NUCLEIC ACID PROBE; DNA probe; HBV; Hep; Hep B; Hep B virus RNA; Hepatis; Hepatit; HepB; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.77 |
2.77 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 103619-3 |
Coagulation surface induced.lupus sensitive.buffer (LA control) |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
Coagulation surface induced.lupus sensitive.buffer (LA control) in Platelet poor plasma by Coagulation assay |
|
ADD |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
103619-3 |
|
Coag |
|
|
Both |
|
|
|
0 |
aPTT.lupus sens.buffer (LA control) PPP |
|
|
|
N |
|
Activated partial thromboplastin time; aPTT; aPTT with Platelin LS; aPTT.lupus sens.buffer (LA control); aPTT-LA; Clot; Clottable; Coag; Coagulation assay; Little(A)PTT; Partial Thromboplastin Time; Plas; Platelet poor plasma; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube |
2.77 |
2.77 |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 10362-2 |
Endomysium Ab.IgA |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Endomysium IgA Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
10362-2 |
|
|
|
|
Both |
|
|
|
0 |
Endomysium IgA Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EMA; Endomysial; Gastro; Gastroenterology; GI; Immune globulin A; Immunoglobulin A; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR; Transglutaminase; UniversalLabOrders |
2.73 |
1.0i |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 103620-1 |
Lupus anticoagulant aPTT screening panel |
- |
PPP |
Pt |
- |
Coag |
|
ACTIVE |
Lupus anticoagulant aPTT screening panel - Platelet poor plasma by Coagulation assay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.COAG |
|
103620-1 |
|
Coag |
|
|
Order |
|
|
|
0 |
LA aPTT screening panel PPP |
|
|
|
N |
|
Anticoag; Anti-phospholipid antibody; Asympt; Asymptomatic; Clot; Clottable; COAGULATION; Coagulation assay; Coagulation inhibiting antibody; dRVVT; LA; LA aPTT screening panel; LAC; Lupus inhibitor; Pan; PANEL.COAGULATION; Panl; Plas; Platelet poor plasma; Pnl; Point in time; Random; Scn; Tilt tube |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 103621-9 |
Small lymphocytic lymphoma chromosome deletions &or rearrangements |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
Small lymphocytic lymphoma chromosome deletions AndOr rearrangements in Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
103621-9 |
|
FISH |
|
|
Both |
|
|
|
0 |
SLL Bld/T FISH |
|
|
|
N |
|
Blood; Chromosom; Chromosomes; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; Point in time; Random; Rearr; Rearrangement; SLL; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103622-7 |
Enterobacter spp DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Enterobacter spp DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103622-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Enterob spp DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Enterob spp; Enterob spp DNA; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.78 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103623-5 |
Enterococcus faecalis+Enterococcus faecium DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Enterococcus faecalis+Enterococcus faecium DNA [Presence] in Specimen by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103623-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
E. fcalis+E. fcium DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; E faecalis; E faecium; E. faecali+E. faecium DNA; E. fcalis+E. fcium; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103624-3 |
Klebsiella pneumoniae + Klebsiella oxytoca DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Klebsiella pneumoniae and Klebsiella oxytoca DNA [Presence] in Specimen by NAA with probe detection |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103624-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
K.pna + K.oxytoca DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; K oxytoca; K oxytoca DNA; K pneumon; K.pna + K.oxytoca; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Pneu; pneum; Pneumo; Pneumon; Pneumonia; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.78 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: updated to reflect nomenclature added space after '+'; |
0 |
| 103625-0 |
Mycobacterium marinum DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium marinum DNA [Presence] in Specimen by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103625-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Mycobact marinum DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; Myco; Mycobact; Mycobact marinum; Mycobact marinum DNA; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Tuberculosis; Unspecified |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 103626-8 |
Mycobacterium ulcerans DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium ulcerans DNA [Presence] in Specimen by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103626-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Mycobact ulcerans DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; Myco; Mycobact; Mycobact ulcerans; Mycobact ulcerans DNA; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Tuberculosis; Unspecified |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
